Citable filing context
STE's research view summarizes recent SEC filing context, starting with management_change from Aug 6, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 6, 2026 | management_change | STERIS plc appointed Pierre Boulud to the Audit Committee and the Compliance and Technology Committee. |
| Aug 6, 2026 | other | STERIS plc held its 2026 Annual General Meeting of Shareholders on July 31, 2026. |
| Aug 5, 2026 | restructuring | STERIS announced a consolidation plan with $55M-$70M in restructuring charges to open a North Carolina facility. |
| Aug 5, 2026 | Guidance: adjusted_eps | 11.10 to 11.30 |
| Aug 5, 2026 | Guidance: capital_expenditures | not reported to 450.00 |
| Aug 5, 2026 | Guidance: constant_currency_organic_revenue_growth | 6.00 to 7.00 |
| Aug 7, 2026 | mda_quarterly | STERIS reported strong financial performance for the first quarter of fiscal 2027, with total revenues rising 7.3% to $1.49 billion. Growth was driven by increased volume in the Healthcare and Life Sciences segments, alongside pricing gains across all three business units: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Gross profit margin improved to 45.8% from 45.1% in the prior-year period, as pricing, productivity, and favorable product mix offset inflationary pressures. Income from operations rose to $285.8 million, up from $246.0 million. The company continues to execute its growth strategy through tuck-in acquisitions, completing three such transactions in the Healthcare segment during the quarter for $17.3 million. While cash flow from operations decreased to $367.1 million due to working capital fluctuations, the company maintains a solid liquidity position with a 20.9% debt-to-total capital ratio. Looking ahead, STERIS announced a new restructuring plan on August 5, 2026, to consolidate formulated chemistries manufacturing into a North Carolina Center of Excellence. This initiative, expected to conclude by fiscal 2030, involves closing facilities in Missouri and Minnesota and is projected to incur $55 million to $70 million in pre-tax charges. Management remains focused on innovation in infection prevention and procedural technologies. |
| May 29, 2026 | mda | STERIS reported fiscal 2026 revenues of $5,935.9 million, an 8.7% increase driven by organic volume growth, pricing, and favorable foreign currency movements. Operating income rose 27.1% to $1,101.8 million, benefiting from higher pricing and a reduction in restructuring and litigation costs. The company’s three reportable segments—Healthcare, AST, and Life Sciences—all experienced growth, with Life Sciences capital equipment revenues notably increasing 15.5%. Gross profit margin expanded to 44.2%, as pricing and productivity gains offset headwinds from inflation and tariffs. Following the fiscal 2025 divestiture of the Dental segment for $787.5 million, which was primarily used to pay down debt, the debt-to-total capital ratio improved to 21.3%. Free cash flow grew to $982.9 million. Key strategic events included the settlement of Illinois EO litigation for $48.2 million and the completion of a restructuring plan targeting the European surgical business. Capital allocation remains aggressive, highlighted by a new $1 billion share repurchase program authorized in May 2026 and increased quarterly dividends. Long-term growth is underpinned by an aging global population and rising demand for preventive screenings, such as endoscopies and colonoscopies. |
Source: SEC EDGAR filing text and events; period Aug 6, 2026; filed Aug 6, 2026.
STE company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.